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1Institutional Polymorphism:
The Designing of the European Food Safety Authority  
with regard to the European Medicines Agency 
David Demortain
1
Abstract
This paper looks at the formation and designing of the European Food Safety 
Authority (EFSA). It seeks to assess the reality of institutional isomorphism in the 
European Union. It does so by analysing why references were made during the 
formation of the EFSA to the European Medicines Agency (EMEA), and the active 
differentiation of its design by actors involved in the process. The paper argues that 
institutional design is the encounter between a political decision to create an 
agency and the norms and practices that constitute sector-specific regulatory 
regimes. Institutional design across sectors derives from the same institutional 
principles, but detailed rules and structures eventually differ because they reflect 
the prevailing conception of the job of the future agency, such as assessing risks or 
approving products, which substantiate and legitimize the decision to establish it. 
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2Introduction 
The proliferation of independent agencies in the European Union seems to make the 
case for institutional isomorphism (DiMaggio and Powell 1983). The independent 
agency as an organizational form is replicated across polities and policy sectors 
(Pollitt et al. 2001). The availability of the legitimated rules and structures that are 
encapsulated in the agency form plays a role in the decision to delegate powers to 
independent agencies (Thatcher 2002).   
This article aims to characterize more precisely the reality of institutional 
isomorphism, by comparing two agencies: the European Medicines Agency 
(EMEA) and the European Food Safety Authority (EFSA).
2
 This comparison is of 
particular value for assessing isomorphic phenomena because comparisons have 
been and continue being made between these two agencies, by scholars
3
 as well as 
by institutional actors. The institutional design used for EMEA provided a point of 
reference for the formation of EFSA.
4
 They both have limited powers and are 
closely linked to their national counterparts through networks of experts or work 
sharing arrangements. When the European Commission first laid out an institutional 
design for EFSA in its White Paper on Food Safety, it sought to replicate the 
successful cooperation between member states that EMEA managed to orchestrate. 
In that respect, EFSA was modelled after EMEA.  
However, the two agencies differ in a number of ways, notably, the procedure for 
risk assessment and decision-making. EMEA prepares decisions, whereas EFSA 
only publishes opinion, which the European Commission uses to make decisions. 
EMEA’s management board comprises representatives of member states, while that 
of EFSA has mostly stakeholders with a few member-state representatives. Finally, 
the experts on the agencies’ scientific committees are appointed by member states 
for EMEA, whereas they are reputed to be fully independent and selected through 
an open procedure by EFSA. 
Despite many references to the EMEA model during the formation of EFSA, the 
participants to the negotiations on the founding Regulation did chose to specific 
design rules and structures which were not borrowed wholesale from EMEA. This 
seems to confirm that there is no unique ‘model’ of Community independent 
agencies (Chiti 2004). The two agencies belong to two different ‘waves’ of creation 
(Kreher 1997). In short, EFSA is not a replica of EMEA in its forms or in its 
success in asserting its authority and becoming institutionalized (Metcalfe 2000, 
Vos 2000, Dehousse 2002, Groenleer 2005). 
2 This agency was previously the European Agency for the Evaluation of Medicinal Products which 
changed its name in 2005 to the European Medicines Agency. However, the original acronym stayed 
in use, and will also be used in this paper. 
3 Vos 2000, Taylor and Millar 2002, Krapohl 2004, Groenleer 2005. See Demortain 2007 for a 
review of this literature. 
4 The legislation that created EMEA was adopted in 1993. It consisted of a Directive that created the 
so-called decentralized procedure of marketing authorization and a Regulation that established the 
centralized procedure and description of the role of EMEA in the running of this procedure. EMEA 
started operating in early 1995 on the basis of Regulation 2309/93/EC. EFSA was set up in 2002 
after the adoption of Regulation 178/2002/EC and became operational in the course of 2003. 
3This paper aims to understand why comparisons, benchmarking and cross-
references between the two European agencies did not result in more isomorphism. 
This question has not been solved so far. Rational choice institutionalism has 
inspired the idea that rules vary from issue-area to issue-area (Pollack 1997), 
without really explaining why. On the other hand, institutional isomorphism has 
been recognized to be a valid argument, but is hardly compatible with the rationalist 
perspective that inspires much of the analysis of institutional design. 
Rather than use norms or interests as a priori and external independent variables, 
this paper develops an approach attentive to the sequence of events and to the 
norms and practices that provided the template for the design of agencies. It defends 
the following idea: the design of agencies is based on the same institutional 
principles, but detailed rules and structures differ because they reflect the norms and 
practices that constitute sector-specific regulatory regimes. The designing of an 
agency is the encounter between a political decision and the prevailing or emergent 
conception of the job of assessing risks and approving products, which substantiate 
and legitimize this very decision. This results in an original pattern of 
‘differentiation yet comparability’ of forms, termed institutional polymorphism. 
This paper focuses on the period of formation of EFSA, from the first proposals 
(including the unsuccessful ones) to the launching of the agency. It uses three kinds 
of data: 24 semi-structured interviews (with Commission officials, officials of 
national food and medicines administration involved in the negotiations in Brussels, 
scientific experts, representatives of interest groups and think tanks, members of the 
European Parliament), insider information collected by public affairs advisers of the 
agro-food and pharmaceutical businesses that tried to influence the formation of the 
agencies, documents such as public and confidential reports, and legislation. 
The paper first discusses the concept of institutional isomorphism to assess whether 
it can fully respond to the research question. It then depicts similarities between 
EFSA and EMEA as two agencies belonging to the field of regulatory agencies, and 
the differences in their design. The third part discusses the way in which political 
imperatives to create agencies encounter sectoral norms and practices through the 
designing of organizational forms.   
Institutional design and isomorphism 
A potential case of coercive or mimetic isomorphism
DiMaggio and Powell (1983) characterize institutional isomorphism as the process 
of imitating organizational forms driven by the taken-for-grantedness and 
legitimacy of organizational forms, rather than by the conscious strategic decision 
to adopt efficient ones. As is well known, the authors have distinguished three 
analytical types of isomorphism:  coercive isomorphism which is driven by political 
imperatives and legitimacy and occurs through imposition of norms or rules; 
mimetic isomorphism which is driven by imitation or emulation between 
organizations, and lastly, normative isomorphism which is driven by professional 
affiliations. 
4Coercive isomorphism could apply to the European independent agencies: the 
principals – the European Commission, member states and the European Parliament 
– chose this organizational form for its legitimacy and imposed it as a political 
imperative. In the particular case of EMEA and EFSA, the network form of 
organization, beyond its alleged efficiency, was the only way to render the creation 
of an agency acceptable and legitimate by preserving the powers of member states 
and the principle of the institutional balance between them (i.e. the Council of 
Ministers and the European Commission). The so-called Meroni doctrine of the 
European Court of Justice holds that the European Commission cannot delegate 
powers it received from member states, as it needs to preserve the balance between 
the powers of the latter and those that are granted to supranational institutions, and 
requires establishing mechanisms of control of the agency (Lenaerts 1993, 
Yataganas 2001). Although this doctrine may have been wrongly applied to the 
case of EFSA (Dehousse 2002), it seems to have played a key role in the process. 
The Commission overcame its reluctance to delegate powers to independent 
agencies (Steinberg 2001) and justified the restriction on powers of the European 
Food Safety Authority through this constitutional rhetoric (Majone 2001), and 
explicitely named the EMEA as a success in the organization of such transnational 
cooperation.
Mimetic isomorphism is also potentially at play here, with institutional actors of 
one policy sector (the area of food safety, embodied by the Commission 
Directorate-General XXIV, called Directorate-General for Health and Consumer 
Protection after 1999) taking as example institutions successfully created in another 
sector, that of pharmaceutical regulation – also concerned with health, but with 
stronger emphasis on objectives such as market integration and industrial 
innovation and under the responsibility of the Commission Directorate-General 
(DG) for Enterprise. At the time that the European Commission drew up plans for a 
European Food Safety Authority, EMEA emerged as a successful form of organized 
regulatory cooperation between member states. This appeared as a way out of the 
conflict between the European Commission, discredited for mismanaging the BSE 
issue, the European Parliament with its fear the that member states would capture 
the agency, and the resistance of member states to delegating more powers to a 
central EU regulatory institution. 
European agencies as sui generis forms 
Nevertheless, as hinted to in the introduction, the two agencies appear too different 
to argue persuasively that isomorphic pressures shaped their structure. The attempt 
to define European agencies has mobilized very generic traits, such as that of 
having a legal legal personality, headed by a management board composed of 
member-states’ representatives, and the product of legislative decision-making 
(Kreher 1997). Similarities can only be understood in highly abstract functionalist 
terms, as in the definition coined by Everson and Majone (1999):  
The essential characteristic of an agency is not its institutional separateness, but its 
functional independence, that is, the decisional autonomy it enjoys with respect to 
some defined policy areas. As long as an administrative office is in complete charge 
of a programme, it is an agency even if it is a sub-part of a larger unit.  
5These definitions do not manage to conceal the great diversity of forms and 
functions of agencies (Commission 2002, Pollitt et al. 2001). The term ‘agency’ 
seems to be nothing more than a label that is applied to highly different 
organizations with some form of independence from governmental organizations 
(Metcalfe 2000). 
Institutional isomorphism hardly has a place here. One explanation is that the two 
European agencies do not belong to the same organizational field. According to 
DiMaggio and Powell, isomorphism takes place between organizations that share 
similar operations and goals, constitute each other’s environment or are under the 
rule of the same political institutions. It is measured through the level of 
homogeneity across this field. 
That EFSA does not resemble EMEA may mean that they are not part of the same 
environment. Indeed, they belong to different policy sectors. Although they belong 
to the same polity, that of the European Union, the complexity and multi-layered 
nature of that polity, in which different principals compete for power, makes it 
unrealistic to think of an over-determination of agency creation by trans-sectoral 
political imperatives and prescriptions coming from the level of the college of 
Commissioners or the Presidency of the Commission. The EU is a highly sectorized 
polity, with few trans-sectoral power arenas (Smith 2004, Carter and Smith 2008). 
As agencies are proposed by particular DGs of the European Commission and the 
founding Regulations are discussed and adopted by sectoral committees of the 
European Parliament and of the Council of Ministers, this limits the potential for 
both coercive and mimetic isomorphism. European independent agencies are 
always sui generis, because their formations are decided and controlled by sectoral 
actors, with few overarching organizational models to draw from. Isomorphism is 
limited to very superficial institutional principles, which take form ‘locally’. It is 
limited to imposing generic requirements of non-autonomous agency or of creating 
‘networks’, that can materialize through very diverse formal or informal rules.  
It may also mean that their operations and goals differ. Approving substances 
submitted by a highly technical and concentrated pharmaceutical industry which 
generates high turnovers, compared to assessing the risks posed by manufactured as 
well as natural substances are exercises which rely on different modes of practice, 
conventions and procedures of decision-making. This is the source of major 
differences between the two agencies, not least in their capacity to receive positive 
commitments from member states and become a source of authoritative assessments 
(Krapohl 2004). 
The determination of organizational forms by regulatory content
The analytical apparatus of institutional isomorphism does not seem to be able to 
explain why the norms and practices of the regulatory process has an influence on 
the designing of an independent agency, arguably a highly political process in 
which ‘principals’ try to secure the capacity to control the future independent agent, 
a process that takes the form of inter-institutional power plays at the European level 
(Kelemen 2002). 
6The new institutionalist framework is limited by its assumption that forms and 
content are separated. As astutely recalled by Fourcade (2006), DiMaggio and 
Powell assume a decoupling between formal traits that disseminate and the 
practices that are invented in their name once imported by an organization: ‘They 
represent diffusion largely as a process of “decoupling” where some external 
features are adopted ceremoniously but contents remain largely determined by local 
processes and institutions’ (Fourcade 2006). This seems to be a structural problem 
of new institutionalism, which allocates much less attention to the work and 
activities of organizations, that is, what is going on inside agencies (Pollitt et al. 
2001, Demortain 2006), than to their forms (Frumkin and Galaskiewicz 2004, 
Hirsch 1997). The rationale consists in assessing similarity and differences between 
different forms, all other things being equal – notably the operations and goals of 
these agencies.  
This separation prevents an analysis of how the regulatory regime, as a complex of 
practices, norms, policies which organize regulatory interventions, can be a source 
of templates and arguments to legitimize certain institutional forms or argue against 
others. The legitimacy of chosen rules and structures may come from their 
perceived efficiency to carry out the regulatory operations and goals. The 
hypothesis explored by this paper is that the regulatory regime is the cognitive and 
normative context within which organizational forms gain their legitimacy, and the 
participants to the formation of the agency with most influence on its forms are 
those that are socialized to this regime. 
Same function, different forms? EFSA compared to EMEA 
Risk regulation as an organizational field 
EFSA was created by a Regulation adopted by the Council of Ministers and the 
European Parliament in 2002. It was launched later that year and stepped up its 
activity progressively in 2003. The creation of EFSA opened a ‘third wave’ of 
independent agencies, after those of the 1970s and of the early 1990s (Kreher 1997). 
Despite their belonging to two different phases of organizational creation, EFSA 
and EMEA can be seen as part of the same organizational field: that of regulatory 
agencies. According to Vos (2003), both EMEA and EFSA are regulatory agencies 
(as opposed to information agencies) in the sense that they make regulatory 
decisions possible by providing the scientific input. The European Commission also 
includes the two agencies in the category of regulatory agencies. They are both 
‘actively involved in the executive function by enacting instruments that help to 
regulate a specific sector. The majority of them are intended to make such 
regulation more consistent and effective by combining and networking at 
Community level activities which are initially a matter for the Member States’ 
(Commission 2002). They both provide assistance in the form of opinions and 
recommendations.
5
5 As opposed to agencies that provide assistance in the form of inspection reports and those 
empowered to adopt individual legally binding decisions (Commission 2002).  
7This classification is underscored by a vision of the European Union as a regulatory 
state, i.e. a state for which regulation is the main form of policy intervention. The 
creation of agencies is typical of regulatory states, as argued by Majone (1999). It is 
a response to challenges on the policy credibility of public authorities. This 
credibility problem is specifically acute for the European Commission. The 
traditional Community method (decentralized enforcement through directives) is 
not adapted to the treatment of increasingly complex technical issues, such as that 
of food and medicines safety, which relate to ‘risk regulation’ (Dehousse 2002). 
Expertise is missing and the degree of politicization of policy-making prevents the 
efficient treatment of these issues (Majone 2000). Furthermore, most of the powers 
of implementation reside with member states, while standards are set at the 
European level. The Commission’s credibility suffers from this regulatory gap, 
which impedes effectiveness. 
In all of these aspects, delegating regulatory functions to independent agencies is a 
solution. It gathers together the necessary expertise, shields regulation from 
political interests and leaves the possibility for the European Commission to turn 
itself into a strategic policy planning administration (Vos 2000, Kelemen 2002). 
Regulatory agencies are particularly beneficial when they take the form of a 
network of national agencies, coordinated at the European level by a European body, 
as it helps to bridge the gap between national and European levels. This is the 
foundation of a ‘structural logic’ (Dehousse 1997) that unites EMEA and EFSA, 
whereby cooperation between national agencies creates convergence, whether or 
not the European agency has authority on national ones, through the diffusion of 
information (Dehousse 1997, Majone 1997). The emergence of a new governance 
underlies the creation of these agencies (Flinders 2004, Eberlein and Krewer 2002). 
Isomorphism, in this case, relates to the emulation of this ‘governance by network’ 
(Dehousse 1997) approach and the organizing of cooperation between member 
states under similar forms. In the case of EMEA, it took the following main forms: 
a centralized procedure of product authorization,
6
 the representation of member 
states in the European scientific committees through national scientific experts and 
on the board of administration of the agency, the redistribution of fees paid by 
pharmaceutical companies to the national agency which evaluated the dossier.  
EFSA and ‘governance by network’ 
It is likely that the European Commission cited EMEA’s governance by network as 
a successful example for emulation and to assert the necessity for EFSA to 
cooperate with national counterparts.
The formation of EFSA is the result of a particular context, the aftermath of the 
‘mad cow’ (hereafter BSE) and dioxin crises. The Commission resigned 
collectively in 1999, under pressure from the European Parliament and from 
accusations linked to the BSE crisis as well as other matters of corruption. Romano 
6 The Committee for Proprietary Medicinal Products (CPMP) would evaluate dossiers submitted 
directly by companies at the supranational level. The decision would be prepared by the CPMP, on 
the basis of the conclusions of a national expert. The agency would support and coordinate the work 
of the CPMP. The evaluation of products is centralized, but member states remain the key 
stakeholders of the system. 
8Prodi, then nominee candidate for the Commission presidency announced in June 
1999, his intention to create a ‘food and drug authority’. Prodi put forward the fact 
that the Commission President should not be held accountable for contaminations in 
the food chain. Creating an agency for scientific advice was an ideal solution for 
shifting the blame.  
The Commission published a White Paper on Food Safety in 1999. At the time, the 
EMEA system of collaboration between member states had proved successful 
enough for the Commission to refer to it as an efficient form to emulate. The 
Commission thus admitted in the White Paper on Food Safety that the example set 
by EMEA had been used to reflect on the design of the future food agency. A year 
after the White Paper, the Commission released the proposal for a Regulation 
establishing EFSA and reforming food law. The following argument was made in 
the explanatory memorandum:
7
It is proposed that the Authority will enlist the expertise of the Member States for the 
drafting of an initial assessment report on the basis of the authorization dossier in 
preparation for final evaluation by one of the specific scientific panels.8 This 
procedure draws on the successful experience of the EMEA which is able to meet 
strict time-limits for the evaluation of dossiers for the authorization of medicinal 
products in the Community. It is therefore intended that, where appropriate, the 
European Food Authority9 may remunerate such competent organizations for their 
assistance with authorization dossiers in order to ensure time delays and common 
quality standards are met. 
This positive reference to EMEA is motivated by the fact that the agency 
successfully managed to orchestrate cooperation between member states for the 
joint authorization of medicines. The Commission intends to emulate that success 
for the authorization of products, which EFSA is competent for (such as pesticides, 
novel foods, genetically modified foods, food and feed additives). 
The politics behind this choice seems quite clear: transnational cooperation 
orchestrated at the European level solves the dilemmas of European integration.
The centralization of more policy-making and regulation at the EU level is limited 
by the lack of resources of the European Commission. Approving products and 
assessing risks are activities, which increased steeply in the 1990s and for which 
there was insufficient Commission staff. The creation of an agency helped to solve 
this shortage. Independent agencies are funded from a different budget to that of the 
European Commission. Creating an agency is a way to attract resources for 
executive activities at the European level, without arousing as much opposition 
from member states as if competences were directly granted to the Commission. 
Agencies’ cooperation with member states also offers the opportunity to increase 
regulatory convergence, even in the absence of a regulatory authority. Soft 
7 Proposal for a Regulation of the European Parliament and of the Council laying down the general 
principles and requirements of food law, establishing the European Food Authority, and laying down 
procedures in matters of food. 
8 National agencies would first carry out an evaluation of the data submitted by a company to have 
its product authorized. In a second step, the conclusions of this evaluation would be reviewed by 
national experts gathered as a committee of the European agency.  
9 The name originally chosen by the Commission, later changed to European Food Safety Authority 
through an amendment adopted by the European Parliament. 
9cooperation through scientific deliberation and exchange of information limit 
discrepancies between national approaches (Majone 1997, Dehousse 1997, Eberlein 
and Grande 2005). An agency thus solves the risk of dissent between scientific risk 
assessments made separately by member states, as was the case during the BSE 
crisis and ‘beef war’ between France and the United Kingdom. 
In this regard, isomorphism did take place: EFSA has been designed, much like 
EMEA, as an independent yet not autonomous agency. Most of its tasks are to be 
carried out in cooperation with national bodies, be it the collection of surveillance 
data or the selection of priority topics.
The inappropriateness of EMEA design for food safety 
However, the coordination and cooperation of member states takes different forms. 
In the case of EFSA, national agencies are not represented in the agency in the same 
way. Firstly, members of the scientific committees of EFSA have no official 
function as representatives of member states. Representing member states directly 
within scientific committees would be unacceptable in the aftermath of the BSE 
crisis, which highlighted the lack of independence of scientists who were advising 
the European Commission on veterinary issues at the national level.
Secondly, the EFSA management board does not comprise national representatives, 
but a variety of stakeholders who represent the different segments of the food chain. 
There again, the lessons drawn from the BSE crisis and the accusations made by the 
European Parliament to the European Commission and member states made 
unacceptable the idea that the agency could be captured or steered by member states 
through its board. Accordingly, the cooperation of national agencies with EFSA, is 
organized through a non-operational advisory forum, in which representatives of 
national food agencies discuss the EFSA working programme.  
The impossibility of replicating these forms is due to the context of the political 
crisis in which the decision to create the EFSA emerged (Clergeau 2005, 
Zwanenberg and Millstone 2005). Following the revelation that the BSE could be 
transmitted to humans and a thorough inquiry into the functioning of the DG for 
Agriculture and the Standing Veterinary Committee, the Commission came under 
very strong pressure from member states and from the European Parliament. It was 
accused of being biased towards industrial interests and of giving priority to the 
objective of achieving the single market over public health. The creation of the 
agency was a crisis-ending strategy for the Commission, to state its willingness to 
put safety first and follow scientific advice of the highest possible quality and 
independence. In the aftermath of the crisis, the main imperative was to separate 
science from politics, or, in the terms of the risk analysis principle (NRC 1983), to 
draw a line between risk assessment and risk management. 
Product approval, and specifically medicine licensing is by comparison a much 
more integrated process, in which all aspects involved – risk/benefit assessment, 
decision concerning the distribution and labelling of the product as well as the 
social and political judgements involved in evaluating the collective need for 
medication and industrial innovation – are absorbed in the evaluation of the 
industrial dossier and managed by professional experts, which retain the authority 
10
to control the entire exercise (Hauray 2005). This is the source of a very high 
degree of independence for the agency in its operations and relations with firms and 
other stakeholders (Abraham and Lewis 2000, Metcalfe 2000, Gehring and Krapohl 
2007).
This model of integration of risk assessment and risk management within the 
professional evaluation of medical experts was incompatible with the prevailing 
concept of food safety. The general belief of participants to food safety policy-
making was that food is a complex matter, with various cultures, values, political 
views and economic interests bearing on decisions concerning the distribution and 
consumption of food products. The assessment of risk should be insulated as far as 
possible from these sources of bias. The scientists involved have no authority to 
arbitrate these aspects to prepare decisions, like medical experts. In such a 
‘politicized’ domain (to use an expression frequently used by actors themselves), 
the authority of scientists must be well circumscribed to risk assessment. 
In contrast with the pharmaceutical regulatory regime in which member states 
wanted to secure their participation to the processes conducted by the European 
agency, this did not appear as the most critical condition in food safety, i.e. risk 
management decisions are in the hands of the Commission and subjected to control 
by member states. This imperative of the independence of the agency and the 
separation between scientific advice and regulatory decision-making guided the 
choice of possible models for the future EFSA away from existing integrative 
models, such as the US Food and Drug Administration which has regulatory power 
(see Alemanno 2006) or EMEA. 
Comparisons with and differentiation from EMEA in EFSA formation
The rules adopted for pharmaceutical regulation were justified by the need to 
facilitate cooperation between national agencies and national experts with an 
extensive regulatory authority. The rules were inappropriate for the creation of a 
food agency, which needed a boundary between the science of risk assessment and 
risk management. The fate of several proposals made by influential actors in the 
process of designing EFSA highlights it. 
The officials of the DG XXIV  kept the idea of a food safety agency alive during 
the transition between the Presidency of Jacques Santer and that of Romano Prodi 
in 1999. In particular, they considered the propositions advanced by a think tank, 
the European Policy Centre (EPC).
10
 The EPC report used EMEA as a benchmark 
for the improvement it brought to product authorization procedures (EPC 1999). 
Medicine licensing was seen as exemplary for the clarity of the requirements and 
professionalism of the evaluation. Food companies considered it necessary to 
emulate this model for the authorization of their own products. A European food 
agency with the power to prepare or issue marketing authorization would be 
preferable to a risk assessment agency, in terms of accountability, performance, 
10 A senior consultant and member of the think tank headed a group of industry experts, who were 
representing major agri-food businesses such as Coca-Cola, Unilever, Masterfoods, etc. The 
intention of the companies in doing so was to bypass the European food trade association which 
originally adopted a negative stance on the creation of a food agency and seemed to be a rather 
inefficient vehicle for lobbying the European Commission on that matter. 
11
legal certainty, and industrial competitiveness. However, the Commission rejected 
the proposal, on the grounds that it would not be in line with the principle of 
institutional balance and the Meroni doctrine to delegate power to prepare or issue 
marketing authorization decisions. 
The Director of the DG XXIV also consulted three senior scientists who were 
members of its main scientific committee, the Scientific Steering Committee. The 
three scientists were asked to create a template for a European food agency
11
. The 
report delivered by these scientists in December 1999 (James 1999) contains an 
assessment of all possible organizational options: an internal Commission service, 
an inter-institutional organization (supervised by the European Parliament, the 
Commission and member states) and an independent agency. EMEA embodied the 
latter solution. The three scientists argued that this solution was inappropriate. They 
felt that firstly, risk assessment and risk management should be separate, and 
member states should not have the right to appoint experts as at EMEA. Secondly, 
risk assessment and risk management institutions must stay geographically close in 
order to ensure the best possible interaction and communication between regulators 
and the scientists that advise them.  At present independent agencies are generally 
granted to member states as part of political deals. They are set up in cities across 
Europe, far from the main location of the European Commission in Brussels. 
In this sense, and in spite of the permanent call for the creation of an agency as 
effective and successful as EMEA in the domain of food safety,
12
 the evidence for 
institutional isomorphism is scarce. Similar functional and political challenges 
concerning the centralization of functions at the EU level meant that the 
‘governance by network’ approach was used in both sectors. But the prevailing 
conception of the appropriate approach to the conduct of risk assessment and the 
regulation of food justified departing from the rules and forms adopted for the 
regulation of medicines. 
Regulation and the legitimization of organizational forms 
How can one explain that the design of an agency is determined by sectoral norms 
and practices of risk assessment and risk management, rather than by cross-sector 
isomorphism? The situation described above is one in which non-sectoral rules and 
actors are overtaken by sectoral ones. This section of the paper seeks to analyse the 
situation. It emphasizes the time dimension to show that the creation of agencies as 
an encounter between a process of regulatory reform and the decision, by principals, 
to adopt a reform and delegate powers. This encounter, however, is dominated by 
sectoral actors and their projects. In this context, the norms and practices of the 
11 In doing this, the DG XXIV was imitating Tony Blair and the British Labour Party which, in 1997, 
asked one of these three scientists, Philip James, to create a blue-print for what was to become the 
UK Food Standards Agency. 
12 Most of the actors who were consulted or tried to influence the design proposed by the European 
Commission referred to EMEA. Members of the European Parliament involved in the discussion of 
the White Paper on Food Safety exchanged ideas with their counterparts who follow pharmaceutical 
issues; officials of DG XXIV with DG Industry; DG XXIV scientific experts with members of the 
CPMP; the food industry European trade association with the European Federation of 
Pharmaceutical Industry and Associations. 
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regulatory regime are the templates through which designs are elaborated and 
legitimized by these actors. 
The sequence of agency formation: the encounter between political action and 
regulatory reform 
There is no doubt that the decision to create an agency is in the hands of principals. 
In the two cases of EFSA and EMEA, the agencies could not have seen the light of 
day without the definitive decision by the respective Commission Presidents, 
Romano Prodi and Jacques Delors, to externalize functions so far performed by the 
European Commission or enter into new forms of collaboration with member states. 
But the designing of the agency only occurs when the political decision to create an 
agency encounters a project of regulatory reform. The successive attempts to create 
a food and a medicines agency show that agencies are not established if only one of 
these two factors comes into play. 
The first proposal to create an agency dates back to the mid-1980s. It was then 
related to the problem of meat hygiene. Deficient controls in the meat sector were 
emphasised by a White Paper as well as a parliamentary report in 1985. An agency 
was seen as a way to strengthen the capacity of the Commission to control national 
inspectorates and to improve compliance with food standards. The idea of 
establishing a European agency resurfaced in the late the 1980s in the context of the 
need to improve the scientific evaluation of novel foods. It was believed at the time 
that an agency could moderate the detrimental effects of unharmonized regulatory 
initiatives by member states. However, the Commission showed sensitivity to the 
industry arguments that an agency would be too bureaucratic and instead proposed 
to step up scientific cooperation between member states through informal scientific 
networks.
The accusations of mishandling of the BSE issue to the Commission explain that 
the creation of a European food agency was frequently called for after 1997. That 
year, Jacques Santer, then President of the Commission, proposed to turn the 
Commission food safety inspectorate into an independent agency, with support 
from Members of the European Parliament (Valverde et al. 1997). Eventually, 
however, the decision was to transform the inspectorate into a separate directorate 
of DG XXIV. This ‘volte-face’ (Kelemen 2002) was linked to an extensive 
evaluation of the organization of food control across European countries,
13
 as well 
as to the difficulty of concentrating regulatory functions in an agency and to break 
13 This included the fifteen member states at the time, the US, New Zealand and Canada. The 
conclusion of this evaluation, made by the Commission Service of Administrative Inspection, was 
that food control formed part of the core regulatory authority of the European Commission and 
should not be delegated. In other words, the regime by which food matters were regulated, of which 
veterinary and sanitary inspections were as important a component as risk assessment is now, 
delegation of functions to an independent body appeared inappropriate. The Commissioner for 
Consumer Protection, Emma Bonnino, visited the US Food and Drug Administration in 1997 and 
concluded that this model could not be adapted for Europe given the regulatory powers granted to 
the FDA and its lack of independence. 
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the modus vivendi existing among the different directorates general involved in 
food matters.
14
The commissioners for consumer protection and for agriculture however raized the 
idea again in 1998, before the European Parliament, as the importance of what was 
then called the ‘scientific instrument’ rose (Commission 1997). Food policy was re-
interpreted as an issue of consumer health and uncertain risks that should be 
properly evaluated. In this context, it appeared legitimate to create an agency to 
distinguish between science and decision-making. 
‘EFSA’s formation is special’ (Buonnano 2006) indeed, because the decision for its 
creation has been an eminently public and political process.
15
 The conception of a 
risk assessment agency is a result of the encounter between a political context in 
which the European Parliament acted as a ‘power maximizer’ in asking for 
guarantees of independence and transparency (Buonnano and Negent 2002), and the 
recognition of the importance of the instrument of risk assessment to address food 
safety issues since Romano Prodi’s strategic decision met with the emerging risk 
analysis principle. 
In a rather different fashion, the creation of the medicine agency was achieved 
thanks to the action of a political entrepreneur, who managed to build consensus 
and attract political support for a decade-old regulatory reform.
In spite of several attempts to reorganize the coordination of the marketing of 
medicines through mutual recognition or through the so-called ‘multi-state’ 
procedure, companies as well as member states made little use of the common 
European procedures (Hauray 2006). A lack of trust between member states and the 
reluctance of pharmaceutical companies to use mutual recognition or multi-state 
procedures plagued the process. These modes of Europeanisation did not prove 
efficient (Feick 2002). In the 1980s, an emerging regulatory crisis was signalled by 
the growing backlog of application dossiers at the national level. Sauer, then head 
of the Commission unit for pharmaceutical products, started to orchestrate and step 
up the cooperation between national experts through a biotechnology scientific 
committee. He began to argue consistently for the necessary coordination of 
product approval at the European level. He drew up long-term perspectives, 
defending the view that product approval would become more and more 
integrated
16
 to match an increasingly concentrated and internationalized 
pharmaceutical industry, and that national authorities were participants and 
competitors within a common system (Hauray and Urfalino 2002). Sauer’s reform 
project became part of the Commission Presidency’s grand political scheme to 
14 Food hygiene and inspections were of the competence of DG VI (Agriculture). Regulation of 
novel foods was a competence of DG III. Consumer protection aspects grew in importance as the 
Service of Consumer Protection was transformed into DG XXIV in 1995. 
15 What reinforced the political nature of this process was the concomitant rise of the European 
Parliament, which gained powers with the entry into force of the new Treaty of the European Union 
of Amsterdam. During the BSE crisis, the Members of the European Parliament maximized the 
opportunity to gain power over the European Commission and made the most out of the 
wrongdoings of the main executive body. 
16 Including at the international level. The European Commission was instrumental in launching the 
process of international harmonization of standards and requirements for medicine licensing, known 
as the International Conference for Harmonisation. 
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achieve the European internal market by 1992 and stakeholders were given 
ownership over it, thanks to skilful political and tactical steering of the reform by 
Sauer (Hauray 2006). 
In other words, the decisive act that launched the concrete designing of rules and 
structures to allow for risk assessment or product approval through an agency at the 
European level, was the result of a rather contingent encounter between long-term 
dynamics of regulatory reform and a political decision.
A sector-contained process 
The particularity of the formation of agencies in the European Union is that this 
politicization does not result in the imposition of particular institutional forms 
because the formation of agencies remains in the hands of sectoral actors.
The language in which the creation of EFSA was phrased is not neutral and 
originates from the dynamics of the sector. The principle of risk analysis was 
originally elaborated by a working group of the National Research Council of the 
United States in the early 1980s (NRC 1983). It was taken up by international 
organizations such as the Joint Expert Committee on Food Additives. But, crucially, 
the BSE crisis broke out after the risk analysis principle had been turned into an 
international rule. A guideline had been developed in the Codex Alimentarius,
17
which states that risk assessment and risk management should be ‘functionally’ 
separated, although not necessarily entrusted to two separate organizations. By then, 
the WTO agreements had been signed and the Codex Alimentarius recognized as 
the reference organization in food-related trade conflicts. This made risk analysis an 
international legal principle and increased the pressure on the European 
Commission to comply with it (Taylor and Millar 2002). 
The use of the risk analysis principle thus follows from a normative climate and the 
active dissemination of the principle within the European Commission by members 
of the Commission’s scientific committees or of the ‘risk assessment’ unit created 
by the DG XXIV in 1997. In the political context faced by the Commission and its 
leaders, this principle became a handy response to a rising health agenda and 
concerns for the use of the ‘scientific instrument’ (Commission 1997) in the face of 
growing uncertainties. It had the virtue of being principle-like: it could be promoted 
as a basic prescription of food law, and thus served as a way to solve the old 
struggles between different administrations, each responsible for a different part of 
a highly fragmented set of food regulations. 
The pharmaceutical reform, which the creation of EMEA symbolized, was steered 
by sectoral actors. The main promoter of the reform of the pharmaceutical 
regulation, Sauer, was a pharmacist by training and made his entire career in the 
area of medicine regulation. His vision for the reform was itself based on that of an 
older regulatory expert from Luxembourg, Léon Robert, who mentored him in the 
European Commission. Robert was involved in the negotiation of the first piece of 
European legislation on pharmaceuticals and acted as chairman of the main 
17 The former is a scientific committee of the World Health Organization. The latter is the 
international body for food standards. 
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European scientific committee for pharmaceuticals (Committee for Proprietary 
Medicinal Products), created in 1975. He repeatedly argued for the creation of a 
central ‘bureau’ or agency for the authorization of medicinal product since the 
1960s.
In both cases, the process leading to the adoption of the founding Regulations is 
carried out within sector-specific arenas. The proposals for Regulations establishing 
these agencies were drawn up by specific units of the European Commission. Their 
authors were officials, which were historically involved in the policy reforms of the 
domain or ‘experts’. The proposals were negotiated by national experts in the 
Council of the European Union. On the food side, the proposal (and the risk 
analysis principle in particular) was discussed and refined during an intense six-
month scrutiny by a dedicated ‘Friends of the Presidency’ group.
18
 In contrast, non-
sectoral actors, such as the Secretariat General of the European Commission, had 
very little influence on the design of agencies.
Regulatory norms and practices as organizational templates 
The particular order of events which lead to the creation of agencies and the 
domination of sector-based actors over the process implies that the norms and 
practices of the sectoral regulatory regime constitute the basis for establishing 
future rules.
19
The creation of an agency involves certain effects on power relationships that are 
hard to predict. Creating an agency means creating new participants, new roles and 
relationships in the regulatory process. The extent to which these participants – 
most notably the agency – will be able to strategically gain from the role they are 
given, to expand and gain more power, is uncertain (Tallberg 2002). Political actors 
are not necessarily as instrumental and far-sighted as they are depicted in the 
literature (Pierson 2000). Norms and practices around risk assessment and risk 
management form a kind of cognitive template (Hall and Taylor 1996), on the basis 
of which actors interpret proposed designs in terms of the consequences on them 
and elaborate new ones. 
The negotiations on the design of EFSA were established in the language and 
vocabulary of the regime. While the risk analysis talk was unused until the mid-
1990s, it became central to the interpretation of the BSE crisis around 1996 and 
1997. The accepted narrative expressed by the European Commission, scientific 
experts, interest groups, members of the European Parliament as well as consumer 
groups, was that an insufficient separation of risk assessment and risk management 
(the capture of DG Agriculture by British veterinarians) led DG Agriculture to 
ignore the emerging BSE problem. The blurring of responsibilities now causes 
consumers to lose confidence in institutions and policies. Hence, consumer 
confidence should be restored by separating risk assessment and risk management.  
18 The member state which holds the rotating Presidency of the Council of the European Union has 
the right to stall the decision-making process and to establish a special expert group to discuss a 
Commission proposal. 
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In Waterton and Wynne’s terms, they constitute the ‘political order’ through which a vocabulary 
and identity for the agency are competitively developed (Waterton and Wynne 2004). 
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The principle of risk analysis, which supported such interpretation, permeated 
parliamentary reports, think tanks, interest group position papers, and 
Commissioners’ speeches. Comparisons with food agencies of other countries and 
ways of separating risk assessment from risk management, were also extremely 
frequent. As noted above, the Commission administrative inspectorate evaluated all 
national models of organization of food control as well as the food agencies of the 
USA, New Zealand and Australia. The EPC experts looked at the agencies which 
were in the course of being created in Ireland, the UK and France. Similarly, the 
recently created medicines agencies in UK and France were mentioned as an 
example to follow by the Commission in its proposal for a Regulation creating 
EMEA.
In the Council, member states asked which institution of the Commission and the 
future agency would be in charge of risk communication or of the establishment of 
guidelines? They also rejected the Commission’s idea to entrust the agency with the 
running of the food alert system on the grounds that the latter imply taking risk 
management measures. Specific questions thus remained on a long list of issues: 
who is accountable for the evaluation of the product, on what grounds should 
experts be nominated, has the applicant the right to choose a member-state for the 
evaluation of its products, has the agency the right to propose ‘risk management 
options’, the publication of its opinions, etc.? After the adoption of the founding 
Regulation in January 2002, Commission and EFSA officials, with the help of 
scientists, elaborated common routines in line with the risk analysis principle. They 
agreed on the presence of a Commission official during meetings of the various 
EFSA scientific panels to facilitate interpretation of the requests coming from the 
Commission and explaining possible legal complications.
20
The formalization of the procedure of pharmaceutical marketing authorization was 
riddled with issues concerning the concrete division of labour between national 
experts and the European CPMP along the process, such as the list of products for 
which the centralized procedure was mandatory, the selection of national delegates 
to the CPMP and the staff and budget of the agency. 
This shows that the designing of rules and structures was negotiated through the 
language of regulation and based on the prevailing conceptions of the central job of 
assessing risks and approving products. The risk analysis principle and the 
centralized procedure imagined by Sauer and his predecessor Robert provided a 
template and language to identify the critical points for the distribution of 
regulatory authority. If there is evidence of isomorphism and imitation of legitimate 
organizational forms, that takes place between organizations or actors which pertain 
to the same regulatory area or share references that constitute the sectoral regime. In 
new institutionalist terms, the ‘organizational field’ of relevance is not that of 
European regulatory agencies, but that formed by all the organizations across the 
different countries, which participate in the regulation of an industry. 
20 Interestingly, the general view in 1999, before the creation of EFSA was that the important 
decision was to separate risk assessment from risk management. As said by Gérard Pascal, one of 
the three senior scientists consulted by DG XXIV, ‘there would always be some time later to 
organize the interaction between the two’ – a choice that meant, in essence, that the designing of 
more precise rules was postponed until after the launch of the agency and delegated to sectoral 
technical actors. 
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Conclusion
EFSA is not designed in the same way as the EMEA because the issues, norms and 
practices that constitute the regulatory regime of each sector influences the 
designing of institutions. In medicine regulation, risk assessment and risk 
management are both owned by medical experts which retain the authority to deal 
with all aspects involved in the process – medical, regulatory and political. This is 
in strong contrasts with the then emerging food regulatory regime, based on the 
principle of the necessary separation of science from politics, and explains why 
certain rules and structures designed for medicine regulation were deemed 
inappropriate for food safety. 
There is polymorphism rather than isomorphism at play here, in the sense of a 
differentiation occurring within a context of comparability. Agencies in each sector 
pose the same sort of issues for the distribution of powers. But this does not justify 
the imposition of an institutional model.  
This helps to understand often heard arguments about the specificity of regulating 
food or medicines. These belong to political strategies which help participants in 
the formation of agencies to put all possible models at a distance. Alleged 
differences between each sector (‘Food regulation is about evaluating risks and is 
more politicized than pharmaceutical regulation, that is about approving products’, 
‘medicine licensing requires the provision of high quality medical evaluations of 
the risk/benefit ratio and keeps marketing time to a minimum’) are not necessarily 
objective. They are strategies, for member states in particular, to prevent the 
imposition of rules and structures from outside the policy domain, owned by the 
European Commission. 
The paper also shows that the conflict between two theoretical views, one based on 
norms and the other on interests pursued by rational actors, can be avoided. Firstly, 
that the effects of norms on agency design are related to particular contexts. 
Analytical frameworks must accommodate the factor of contingency and the 
particular order of events. Secondly, it appears that norms and practices of the 
regulatory regime are the language or templates through which rational actors can 
formulate their preferences. There is no such thing as the pure ‘interest’ of rational 
institutional actors, influencing the process as the deux ex machina. The 
particularity of the cases investigated here is, finally, that the rational preferences of 
institutional actors and norms converge. In a situation in which political and 
regulatory dynamics are contained within the boundaries of domains (Breyer 1993, 
Hood et al. 2001), the specificity of practices is by default favourable to actors who 
try to distance from institutional traditions, to design rules to their liking. In that 
sense, institutional designing is a form of regulatory action, and institutional 
creation a sequence of regulatory change. 
18
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